Xeris exchanges $23M convertible notes for cash and stock

Xeris Biopharma agreed to retire approximately $23 million of 8.00% Convertible Senior Notes due 2028 through private exchanges, reducing annual interest expenses by roughly $2 million. The transaction involves cash payment plus approximately 4.6 million common shares, strengthening the company's balance sheet while reducing debt obligations.